



OPEN

Increased $Ca_v1.2$ late current by a *CACNA1C* p.R412M variant causes an atypical Timothy syndrome without syndactyly

Junichi Ozawa^{1,2}, Seiko Ohno^{1,3}, Dario Melgari⁴, Qi Wang^{1,5}, Megumi Fukuyama¹, Futoshi Toyoda⁶, Takeru Makiyama⁷, Masao Yoshinaga⁸, Hiroshi Suzuki², Akihiko Saitoh², Tomohiko Ai^{9,10} & Minoru Horie¹✉

Timothy syndrome (TS) is a rare pleiotropic disorder associated with long QT syndrome, syndactyly, dysmorphic features, and neurological symptoms. Several variants in exon 8 or 8a of *CACNA1C*, a gene encoding the α -subunit of voltage-gated Ca^{2+} channels ($Ca_v1.2$), are known to cause classical TS. We identified a p.R412M (exon 9) variant in an atypical TS case. The aim of this study was to examine the functional effects of *CACNA1C* p.R412M on $Ca_v1.2$ in comparison with those of p.G406R. The index patient was a 2-month-old female infant who suffered from a cardio-pulmonary arrest in association with prolonged QT intervals. She showed dysmorphic facial features and developmental delay, but not syndactyly. Interestingly, she also presented recurrent seizures from 4 months. Genetic tests identified a novel heterozygous *CACNA1C* variant, p.R412M. Using heterologous expression system with HEK-293 cells, analyses with whole-cell patch-clamp technique revealed that p.R412M caused late Ca^{2+} currents by significantly delaying $Ca_v1.2$ channel inactivation, consistent with the underlying mechanisms of classical TS. A novel *CACNA1C* variant, p.R412M, was found to be associated with atypical TS through the same mechanism as p.G406R, the variant responsible for classical TS.

Timothy syndrome (TS) is a rare pleiotropic disorder associated with long QT syndrome (LQTS, type 8), congenital heart disease, syndactyly, dysmorphic features, immunodeficiency, intermittent hypoglycemia, and neurologic symptoms including autism, seizures, and intellectual disability^{1,2}. TS is caused by missense variants in *CACNA1C*, the gene encoding the α -subunit of voltage-gated Ca^{2+} channels ($Ca_v1.2$)^{2,3}. A functional study showed that p.G406R in exon 8a, which is responsible for TS1, significantly slowed the voltage-dependent inactivation (VDI) kinetics, resulting in sustained late Ca^{2+} currents¹. Although syndactyly is a common feature of the classical form of TS1, two atypical patients who showed severe cardiac deficits did not have syndactyly; furthermore they differed genetically, and thus were later categorized as TS2⁴. TS2 patients were found to carry heterozygous missense variants, p.G406R and p.G402S, in a mutually exclusive exon 8. Exon 8 is more predominantly expressed in the heart compared to exon 8a. It is thought that the different expression levels of two transcripts containing either exon 8a or 8 account for those different phenotypes; TS1 patients exhibit a more severe form of extra-cardiac features than TS2^{1,4}.

We experienced a female infant who suffered from cardiac arrest due to Torsade de Pointes (TdP) in association with Timothy syndrome without syndactyly, which mimics TS2. The patient also presented developmental delay and was complicated with recurring seizure attacks. We identified a heterozygous de novo *CACNA1C* variant p.R412M that was located six amino acids downstream to G406R and between domain I-S6 (IS6) and

¹Department of Cardiovascular Medicine, Shiga University of Medical Science, Seta-Tsukinowa, Otsu, Shiga 520-2192, Japan. ²Department of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. ³Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center, Suita, Japan. ⁴Institute of Molecular and Translational Cardiology (IMTC), IRCCS Policlinico San Donato, 20097 San Donato Milanese, Milan, Italy. ⁵Department of Physiology, China Medical University, Shenyang, Liaoning, China. ⁶Department of Physiology, Shiga University of Medical Science, Otsu, Japan. ⁷Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan. ⁸Department of Pediatrics, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan. ⁹Department of Clinical Laboratory Medicine, Juntendo University School of Medicine, Tokyo, Japan. ¹⁰Department of Medicine, Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, USA. ✉email: horie@belle.shiga-med.ac.jp




Figure 1. Electrocardiograms (ECG) of a 2-month-old female infant with Timothy syndrome, showing (A) T-wave alternans, (B) 2:1 atrio-ventricular block and torsades de pointes, (C) before and after the intravenous mexiletine, and (D) after oral administration of mexiletine and propranolol. Red arrows in (B) and (C) indicate P waves.

$\alpha 1$ interacting domain (AID). The AID is known as the binding site for ancillary β -subunit, a potent modulator of voltage-dependent calcium channels. In the present study, we described the clinical phenotypes of the patient and analyzed the functional effects of p.R412M variant on $Ca_v1.2$. We also conducted the functional assay of the p.G406R, a variant found in TS1.

Results

Clinical features of index patient. The patient was a 2-month-old female infant born after 37 weeks of gestation with a birth weight of 2730 g. Fetal bradycardia had been identified at gestational age of 33 weeks, but no cardiac rhythm disorder was noted at birth. Her face was characterized by dysmorphic features such as high arched palate, full cheeks, and congenital clasped thumb, but no syndactyly. At 2 months, she experienced her first episode of syncope due to repetitive TdPs that degenerated into VF.

Her ECG revealed typical T wave alternans, markedly prolonged QT-intervals (RR = 570 ms, QT = 501 ms, QTc = 664 ms, Fig. 1A), 2:1 atrio-ventricular (AV) block, and recurrence of TdP (Fig. 1B). The echocardiography showed no congenital heart defects nor hypertrophy. We suspected LQTS type 3 (LQT3) from the T-wave morphology, depicting a late-onset peaked T-wave. Therefore, mexiletine was administered as an initial therapy. An intravenous injection of mexiletine (1.5 mg/kg) followed by the maintenance dose of oral mexiletine (30 mg/kg/day) resolved the 2:1 AV block to a 1:1 conduction (Fig. 1C). In addition, we started propranolol (2 mg/kg/day), which suppressed recurrence of TdP.

The patient also suffered from recurrent seizures unrelated to TdPs from 4 months after birth. An electroencephalogram at the age of 7 months displayed hypsarrhythmia. She showed severe developmental disability and hypotonia, and thus she was barely able to roll over at the age of 3. The patient was also diagnosed with autism spectrum disorder at the age of 2. There were no findings that indicated hypoglycemia or immunodeficiency related to TS.

With the medications, the patient's ECG at the age of 5 showed slightly prolonged QTc (RR = 559 ms, QT = 346 ms, QTc = 462 ms; Fig. 1D). Since the pharmacotherapy successfully suppressed her TdP, implantable cardioverter-defibrillator (ICD) was not implanted. Unfortunately, the patient suddenly passed away at 5 years old during a nap. Her family history was negative for SCD, LQTS, arrhythmia, or neurological abnormalities.

Genetic analysis. Genetic tests using a gene panel as described in the “Methods” section identified a novel heterozygous missense variant p.R412M in *CACNA1C*. This variant was confirmed by the Sanger method (Fig. 2A). The arginine at position 412 is highly conserved among different species (Fig. 2B). The patient's parents were both negative for this variant, indicating a de novo mutation within this family. Their paternity and maternity were confirmed by screening 12 rare single nucleotide polymorphisms (data not shown).




Figure 2. (A) Electropherograms of WT and p.R412M. (B) Alignment of p.R412M. (C) Topology of $Ca_v1.2$ α -subunit (S, segment; D, domain) with classical TS (TS1, pink circles), TS2 (orange triangles), or atypical TS (yellow diamond)-related mutations. TS1, Timothy syndrome type 1; TS2, Timothy syndrome type 2; Atypical TS, Atypical Timothy syndrome; AID, $\alpha 1$ interacting domain.

Figure 2C illustrates a topology of *CACNA1C* in which known TS-related mutations identified to date are highlighted. The variant identified in this study is indicated in red (with an arrow). Arginine 412 is located in the inner loop of the membrane, between IS6 and binding site for ancillary β -subunit (AID). The p.R412M variant has not been previously reported in at least two online databases: TOGOVAR (<https://togovar.biosciencedbc.jp/>) and gnomAD (<https://gnomad.broadinstitute.org/>). The variants with functional evidence were confirmed as pathogenic based on the American College of Medical Genetics and Genomics (ACMG) guideline for the interpretation of sequence variants⁵.

Functional analysis. Electrophysiological parameters. We examined the electrophysiological characteristics of WT, R412M, and G406R $Ca_v1.2$ channels. Figure 3A shows representative current traces recorded from HEK-293 cells transiently transfected with WT (left), R412M (right upper), or G406R (right lower) *CACNA1C*. Maximal peak current densities were not significantly different among the three types of cells ($I_{Ca,WT}$: -12.3 ± 0.95 pA/pF at +20 mV, $I_{Ca,R412M}$: -10.9 ± 0.75 pA/pF at +10 mV, $I_{Ca,G406R}$: 11.0 ± 1.7 pA/pF at +10 mV; $p = 0.42$). In contrast, the inactivation decay of reconstituted Ca^{2+} currents was significantly slower in R412M- and G406R-transfected cells compared to those with WT ($I_{Ca,WT}$). Table 1 summarizes the biophysical parameters measured from multiple cells.

Figure 3B shows plots of current–voltage (IV) relationships of $I_{Ca,WT}$ (black), $I_{Ca,R412M}$ (red), and $I_{Ca,G406R}$ (blue). The voltage at the peak inward currents was more leftward-shifted in $I_{Ca,R412M}$ and $I_{Ca,G406R}$ than in $I_{Ca,WT}$. Figure 3C shows the steady-state activation at various test potentials for $I_{Ca,WT}$, $I_{Ca,R412M}$, and $I_{Ca,G406R}$. Experimental data were fitted with the Boltzmann function described in the “Methods” section (Eq. (2)). The steady-state activation (SSA) curves for $I_{Ca,R412M}$ and $I_{Ca,G406R}$ were significantly shifted toward negative compared to $I_{Ca,WT}$ (Table 1).

Ca²⁺ current inactivation decay was significantly delayed by the variants found in TS. The decay of I_{Ca} during depolarization represents fast and slow kinetics, which mainly correspond to Ca-calmodulin-dependent (CDI) and voltage-dependent inactivation (VDI), respectively. Therefore, the time course of Ca^{2+} current decay was fitted to a double exponential function to evaluate time constants for fast and slow components (τ_{fast} and τ_{slow} ; Eq. (3)). In Fig. 3D, τ_{fast} and τ_{slow} are plotted against test potentials (from 0 to +20 mV). The τ_{fast} values for $I_{Ca,R412M}$ and $I_{Ca,G406R}$ were significantly larger than those for $I_{Ca,WT}$, while the relative amplitude of the fast component (A_{fast}) of $I_{Ca,R412M}$ was comparable to that of $I_{Ca,WT}$ (Table 1). As for the slow component that is largely attributable




Figure 3. (A) Three sets of representative current traces for WT, R412M, and G406R I_{Ca} elicited by the protocol shown in the inset. (B) peak current density–voltage relationships, (C) steady state activation curves and (D) inactivation time constants for three different I_{Ca} : WT (black circles, $n = 18$), R412M (red squares, $n = 10$) and G406R (blue diamonds, $n = 5$). * $P < 0.05$ R412M vs. WT. † $P < 0.05$ G406R vs. WT. * $P < 0.05$ R412M vs. G406R.

to VDI, the τ_{slow} values were significantly larger and the relative amplitudes were smaller than $I_{Ca,WT}$ for both in $I_{Ca,R412M}$ and $I_{Ca,G406R}$.

Figure 4A depicts three sets of current traces elicited by a double-pulse voltage protocol (inset panel). Both $I_{Ca,R412M}$ and $I_{Ca,G406R}$ showed the persistent late inward Ca^{2+} currents even at the end of 500-ms test pulse. In Fig. 4B, the peak inward current amplitudes measured at +20 mV from various test potentials were normalized against their maximal values and are plotted as a function of test voltage. Experimental data were then fitted with the Boltzmann function (Eq. (2) in “Methods” section) to calculate the half-maximal voltage of inactivation (Table 1). While $I_{Ca,WT}$ were completely inactivated at +20 mV, $I_{Ca,R412M}$ and $I_{Ca,G406R}$ were not inactivated even at +50 mV (maximal inactivation level of 78% and 54%, respectively). Compared to $I_{Ca,WT}$, the voltage-dependency of steady-state inactivation (SSI) was rightward-shifted to the positive by 7.7 mV in $I_{Ca,R412M}$ and 1.8 mV in $I_{Ca,G406R}$ (Table 1). Figure 4C depicts both activation and inactivation curves for $I_{Ca,WT}$, $I_{Ca,R412M}$, and $I_{Ca,G406R}$ on the same scale. Due to the negative shift of the activation gate and drastic positive shift of the inactivation gate, the window current (I_w) markedly increased in both R412M (red) and G406R (blue) Ca_v1.2 channels. Referencing a previous report⁶, we then calculated the I_w by first multiplying SSA and SSI to give the open probability of L-type calcium channels ($P_o(V)$) (Fig. 4C, dotted curves), and then multiplied by G_{max} and the driving force ($V - V_{rev}$) to estimate the amount of I_w in WT (black), R412M (red) and G406R (blue) Ca_v1.2 channels (Fig. 4D: Eq. (4) in “Methods” section). This kind of I_w quantification clearly represents that I_w of R412M and G406R Ca_v1.2 channels were larger than that of WT.

p.R412M variant mainly affected voltage-dependent inactivation. TO further investigate whether p.R412M Ca_v1.2 channels are affected by alterations of VDI or CDI, we examined characteristics of Ca_v1.2 using barium (Ba^{2+}) as a charge carrier, which allowed us to exclude CDI as previously described⁷. Fig. 5A presents typical current traces of I_{Ca} and I_{Ba} in two different HEK-293 cells expressing WT or R412M Ca_v1.2 after adjusting the peak inward current levels. We then compared the inactivation time course of $I_{Ca,WT}$ vs. $I_{Ba,WT}$ (left) as well as $I_{Ca,R412M}$ vs. $I_{Ba,R412M}$ (right). When Ca^{2+} ions were present as a charge carrier, the inactivation process was accelerated, indicating the presence of CDI. The degree of CDI was estimated by measuring the ratio of currents remaining at the end of 200-ms depolarization to peak inward currents (r_{200}). The values of r_{200} thus calculated are plotted as a function of test potential in Fig. 5B. Then, as shown by Eq. (5), the extent of CDI was evaluated as f_{200} , the fraction of current reduction from I_{Ba} to I_{Ca} ($r_{200,Ba} - r_{200,Ca}$)^{7,8}. The values of f_{200} or the component of CDI are plotted against test potentials (Fig. 5C). These values were not significantly different between WT and R412M, indicating that the variant did not significantly affect the CDI but slowed the current decay through the VDI process as shown by time constants of inactivation (Fig. 3D).

Finally, we examined the steady-state inactivation of $I_{Ba,R412M}$ through a double voltage pulse method used in the experiment shown in Fig. 4. Figure 5D shows the voltage-dependency of steady-state inactivation for WT and R412M Ca_v1.2 currents with Ba^{2+} ion as a charge carrier. The VDI measured as $I_{Ba,R412M}$ was also rightward

Biophysical parameter		WT	R412M	G406R
Activation parameters		(n = 18)	(n = 10)	(n = 5)
Peak density (pA/pF)		-12.3 ± 0.95	-10.9 ± 0.75	-11.0 ± 1.7
V _h (mV)		1.9 ± 1.3	-3.7 ± 1.3*	-9.2 ± 1.2 [†]
k		7.8 ± 0.23	5.7 ± 0.23*	5.1 ± 0.40 [†]
Conductance parameters		(n = 18)	(n = 10)	(n = 5)
V _{rev} (mV)		72.5 ± 1.3	62.8 ± 2.1*	60.8 ± 2.0 [†]
Peak density (pS)		0.26 ± 0.025	0.22 ± 0.056	0.17 ± 0.013
Inactivation parameters		(n = 15)	(n = 12)	(n = 6)
I _{Ca} V _h (mV)		-11.8 ± 1.4	-4.1 ± 1.4*	-10.0 ± 2.0
I _{Ca} k		-8.2 ± 1.1	-7.8 ± 0.65	-6.6 ± 0.52 [†]
I _{Ba} V _h (mV)		-21.7 ± 6.3	-12.1 ± 5.9 *	NA
I _{Ba} k		-12.9 ± 2.9	-12.1 ± 4.7	NA
Inactivation		(n = 18)	(n = 10)	(n = 5)
τ _{fast} (ms)	0 mV	18.7 ± 2.0	24.0 ± 1.8	35.8 ± 4.8 [†]
	+10 mV	15.0 ± 0.8	25.5 ± 1.6*	38.0 ± 7.2 [†]
	+20 mV	15.6 ± 0.7	31.0 ± 2.7*	39.9 ± 2.3 [†]
A fast/A peak	0 mV	0.51 ± 0.015	0.55 ± 0.033 [‡]	0.41 ± 0.034
	+10 mV	0.52 ± 0.0092	0.50 ± 0.012 [‡]	0.29 ± 0.044 [†]
	+20 mV	0.46 ± 0.010	0.40 ± 0.013	0.18 ± 0.019 [†]
τ _{slow} (ms)	0 mV	165.5 ± 26.6	400.0 ± 102.8	387.7 ± 161.3
	+10 mV	123.4 ± 6.6	347.5 ± 75.3*	346.6 ± 135.4
	+20 mV	105.0 ± 5.6	251.3 ± 39.5*	244.6 ± 37.8 [†]
A slow/A peak	0 mV	0.37 ± 0.010	0.23 ± 0.017*	0.22 ± 0.031 [†]
	+10 mV	0.40 ± 0.0063	0.31 ± 0.022*	0.30 ± 0.025 [†]
	+20 mV	0.48 ± 0.010	0.42 ± 0.021	0.34 ± 0.019 [†]
A steady/A peak	0 mV	0.15 ± 0.020	0.30 ± 0.039*	0.42 ± 0.013 [†]
	+10 mV	0.082 ± 0.0081	0.21 ± 0.034*	0.45 ± 0.048 [†]
	+20 mV	0.055 ± 0.0057	0.60 ± 0.39*	0.48 ± 0.023 [†]

Table 1. Biophysical parameters of Ca_v1.2 WT, R412M and G406R channels. Peak current density of activation was measured at +20 mV for WT and at +10 mV for R412M. Peak conductance was measured at +40 mV. NA not available. **P* < 0.05 R412M versus WT. [†]*P* < 0.05 G406R versus WT. [‡]*P* < 0.05 R412M versus G406R.

shifted toward the positive direction by 9.6 mV compared to I_{Ba,WT}. Maximal inactivation of I_{Ba,R412M} still remained 66%, indicating that the failure of VDI is indeed the main cause for drastically slowed current decay as previously reported in G406R variant^{1,4}.

Discussion

In the present study, we found a novel *CACNA1C* variant, p.R412M, in a female infant. The variant is located in an α-helical domain between IS6 and AID, close to two previously reported TS variants: p.G406R found in TS1 (exon 8a)^{1,2} or TS2 (exon 8)^{2,4} (Fig. 2C). Functional analyses using a heterologous expression system revealed that p.R412M caused a hyperpolarizing shift of SSA gate (Fig. 3C) and a drastic depolarizing shift of SSI gate (Fig. 4B), resulting in a greater window current (Fig. 4D) and persistent late Ca²⁺ currents at membrane potentials more positive than -20 mV. Changes in SSA and SSI for I_{Ca, G406R} observed in our experimental condition were consistent with previous reports^{1,4,9}. For the measurement of SSI, they used a 2-s pre-pulse duration, while we used a pre-pulse of 500 ms. However, Ferreira et al. indicated that inactivation of I_{Ca} required longer than 5 s to reach steady state¹⁰. Therefore, only the fast component of inactivation may have been studied in our study. In the study of heterozygous TS2-neo mice, the G406R variant shifted SSI leftward with a pre-pulse of 5 s⁶, which might be more precise for I_{Ca, G406R}.

It has been reported that two types of mechanisms, VDI and CDI, are involved in the inactivation of I_{Ca}. Experiments using I_{Ba} revealed that p.R412M mainly affected VDI. Therefore, its overall biophysical effects were similar to those of p.G406R, causing the very severe TS-related cardiac phenotypes in our patient.

The IS6-AID linker, where the arginine at position 412 is located in, provides physical interactions between the Ca_v1.2 β-subunit and the channel pore. This interaction between two domains is thought to be pivotal for the smooth VDI gating of the channel¹¹. Previous studies showed that an increased rigidity of the IS6-AID linker decelerates the time course of Ca_v1.2 VDI^{11,12}. This rigid stabilization was proposed to be the pathophysiological mechanism behind the G406R variant (both in TS1 and TS2), which critically slowed the inactivation kinetics¹². As the topological location is close to these classical TS mutations, p.R412M may also increase the rigidity of the IS6-AID linker, thereby slowing the VDI process.




Figure 4. (A) Three sets of representative current traces for WT, R412M, and G406R I_{Ca} elicited recorded by a double step pulse protocol in the inset. (B) inactivation voltage-dependence curves for WT (black circles, $n = 15$) and R412M (red squares, $n = 12$) and G406R (blue diamonds, $n = 6$) I_{Ca} . (C) Both activation and inactivation curves are plotted on the same scale. The probability of channel opening $P_o(V)$ curves were obtained by multiplying G/G_{max} by I/I_{max} (dotted curves). (D) The window currents (I_w) calculated by multiplying $P_o(V)$ by G_{max} and the driving force ($V - V_{rev}$) and were normalized by the maximum I_w at 0 mV in G406R. V_{rev} means reversal potential.

Our index patient presented a marked QT-prolongation that was longer than the QT-intervals in TS1 patients¹, with a more severe cardiac phenotype than those observed in reported TS1 cases. Therefore, the clinical features of our patient resembled those of TS2 patients. The variant p.G406R in TS1 is translated from exon 8a, and the variant p.R412M found in our patient is translated from exon 9. It has been reported that expression levels of the *CACNA1C* transcript containing an alternatively spliced exon 8a represent approximately only 20% of the total cardiac *CACNA1C* transcript, while exon 9 is 100% translated since no alternative transcripts exist^{1,2,4,13}. In contrast, the majority of cardiac *CACNA1C* transcripts contain the mutually spliced exon 8. Thus, TS2 patients bearing p.G406R in exon 8 might show severe cardiac phenotypes comparable to p.R412M^{2,4}. These differences in genetic backgrounds may account for the various severity of clinical outcomes^{1,2,4}.

Although we observed that the R412M mutation did not affect the CDI largely just as the p.G406R variant previously found in classical TS patients, Dick et al. demonstrated that the G406R mutation caused significant defects in CDI of the channel⁸. They co-expressed β_2a auxiliary subunit which decreased VDI in Ca^{2+} channels in order to examine CDI precisely. However, we used β_2b auxiliary subunit according to the previously reported “Methods” section⁷. Therefore, we could not deny the CDI impairment by R412M in situ hearts.

TS is an extremely rare syndromic disease, and approximately 50 cases have been described to date². Later on, variants located outside of exon 8/8a were identified: p.E407G, p.E407A, p.G419R, p.S643F, p.C1021R, p.E1115K, p.I1166T, p.A1473G, and p.G1911R in atypical TS patients (Fig. 2C)^{14–22}. More recently, a wide variety of phenotypes in *CACNA1C* variant carrier have been reported, including those expressing only cardiac features or even long QT syndrome (LQT8) alone^{17,23–25}.

Considering that the heart is the most frequently affected organ in TS, ECG would be a useful tool to diagnose and determine the prognosis. As seen in our patient, key features are: extremely prolonged QT intervals ($QTc > 600$ ms); 2:1 atrio-ventricular block and recurrent TdP; and macroscopic T-wave alternans. These ECG changes in TS are more prominent compared to the other congenital LQT8s. When encountering such cases, irrespective of presence or absence of extra-cardiac phenotypes, it would be of clinical importance to conduct genetic testing including that of *CACNA1C*.

Limitation

We could not completely exclude the possibility that other variants might contribute to extracardiac symptoms because a whole exome or genome sequencing was not done. We conducted an electrophysiological study using *CACNA1C* cDNA containing alternative exon 8a. We did not confirm whether a *CACNA1C* variant, p.R412M, caused the same electrophysiological effects on $Ca_v1.2$ when exon 8 expressed. In addition, for the measurement




Figure 5. (A) Four sets of representative current traces from two different cells expressing either WT (left) or R412M (right) *CACNA1C* as Ca^{2+} (black, I_{Ca}) or Ba^{2+} (red, I_{Ba}) as a charge carrier at 0 mV (upper panel) and +20 mV (lower panel). (B) Voltage-dependencies were evaluated as r_{200} (B) and f_{200} (C) at various depolarization for WT (n = 5) and R412M (n = 5) and are plotted as a function of test membrane potentials. (D) Using the double pulse protocol as shown in Fig. 4A, the voltage-dependency of I_{Ba} inactivation was examined for WT (filled black circles, n = 10) and R412M (filled red squares).

of SSI, we employed a short pre-pulse duration, which may have caused ‘quasi’-steady state inactivation and window current.

Conclusion

In a female infant with the atypical TS mimicking TS2 features and sudden cardiac death, we identified a novel heterozygous *CACNA1C* variant, p.R412M. Functional assay of p.R412M showed a significant VDI deceleration of $Ca_v1.2$ channel, consistent with the TS1 variant p.G406R. Our study indicates that patients with TS who carry pathogenic *CACNA1C* variants should be carefully observed to prevent unexpected sudden cardiac death.

Methods

Genetic screening. In accordance with study protocol that was approved by the review board at Shiga University of Medical Science and complied the principles of the Declaration of Helsinki, genetic analysis was performed after written informed consent was obtained from the parent of the proband. Genomic DNA was extracted from peripheral blood leukocytes. Coding and splice-site regions of 56 genes including LQTS-related genes (Supplementary Table 1) were all screened via targeted gene sequencing using a next generation sequencer (Miseq, Illumina, San Diego, CA, USA)²⁶. For confirmation, direct DNA sequencing was conducted on an ABI PRISM-3130 Sequencer (Applied Biosystems, Foster City, CA, USA). The GenBank accession number of *CACNA1C* is NM_000719.6. We confirmed the pathogenicity of the variants according to Varsome (<https://varsome.com/>) and ACMG guideline for the interpretation of sequence variants⁵.

Mutagenesis and transient transfection. The human wild-type (WT) *CACNA1C* cDNA (NM_000719), which contains alternative exon 8a, in a pcDNA vector, and cDNAs of *CACNB2b* and *CACNA2D1*, both cloned into a pcDNA3.1 vector, were used. The vectors were kindly donated by Prof. Charles Antzelevitch (Lankenau Institute for Medical Research, USA). Site-directed mutagenesis was performed using a QuickChange II XL kit (Stratagene, La Jolla, CA, USA). Mutated genes, *CACNA1C* R412M and G406R, were functionally expressed in human embryonic kidney (HEK) 293 cells. HEK-293 cells were co-transfected with WT or mutant *CACNA1C* cDNAs (1 μ g each) along with *CACNB2b* (1 μ g), *CACNA2D1* (1 μ g), and Green Fluorescence Protein (GFP, 0.25 μ g) using 6 μ l of Fugene 6 (Roche Diagnostics, Indianapolis, IN, USA). Cells were employed for electrophysiological experiments 24–36 h after transfection.

Electrophysiology. A whole-cell mode patch-clamp technique was employed to measure WT and mutant Ca^{2+} currents at 25–26 °C using an Axopatch 200B patch-clamp amplifier (Axon Instruments, Foster City, CA, USA). We used 1 μM of nisoldipine to dissect reconstituted L-type calcium currents (I_{Ca}) by digital subtraction. The extracellular (bath) solution contained (mmol/L): 130 NMDG-Cl, 5 KCl, 15 CaCl_2 (or BaCl_2), 1 MgCl_2 , and 10 HEPES. The pipette solution contained (mmol/L): 120 CsCl, 2 MgCl_2 , 2 MgATP , 10 HEPES, 5 CaCl_2 , and 10 EGTA (pH was adjusted to 7.25 with CsOH)⁷. Free Ca^{2+} concentration in the pipette solution was adjusted to be 100 nM by adding appropriate amounts of CaCl_2 calculated by the Patcher's Power Tools package (Igor Pro™ Tool software, version 1.0.6, 1997, © 1995–1997, Dr Francisco Mendez, Dept. of Membrane Biophysics, MPIIbpc Gottingen, Germany). Patch pipettes were prepared using a P-97 puller (Sutter Instruments, Novato, CA, USA) and were fire-polished to a final resistance of 2–3 M Ω .

To study the voltage dependence of channel activation, a single-step voltage protocol was used: depolarizing test pulses with 1-s durations were applied between –50 and +40 mV in 10 mV increments from a holding potential of –70 mV. Data were analyzed using Clampfit (Axon Instruments, Sunnyvale, CA, USA) and fitted with Igor Pro or Prism 7 (GraphPad Software Inc. ver.9). Peak current densities at each potential were obtained by dividing the cell capacitance.

Ca current–voltage ($I_{\text{Ca}}-V$) curves were fitted with the Boltzmann function of the following form:

$$I_{\text{Ca}}(V) = G_{\text{max}} \times (V - V_{\text{rev}}) / \{1 + \exp [(V_h - V)/k]\}, \quad (1)$$

where $I_{\text{Ca}}(V)$ indicates I_{Ca} (pA/pF) at the membrane potential of V (mV), G_{max} is maximum conductance density, V_{rev} is the reversal potential, V_h is the activation midpoint voltage, and k is the slope factor which determines the voltage dependence of channel activation.

The steady-state activation (SSA) and inactivation (SSI) curves were fitted with Boltzmann function of the following form:

$$\begin{aligned} G/G_{\text{max}}(V) &= 1 - 1/\{1 + \exp [(V - V_h)/k]\} \quad \text{or} \\ I/I_{\text{max}}(V) &= 1/\{1 + \exp [(V - V_h)/k]\}, \end{aligned} \quad (2)$$

where $G/G_{\text{max}}(V)$ indicates normalized I_{Ca} SSA, and $I/I_{\text{max}}(V)$ SSI at the membrane potential V , respectively.

To obtain the inactivation time constant, the time course of inactivating currents for the first 300 ms at 0, +10, and +20 mV were fitted with a double exponential function:

$$I_{\text{Ca}}(t) = A_0 + A_f [1 - \exp (-t/\tau_f)] + A_s [1 - \exp (-t/\tau_s)], \quad (3)$$

where $I_{\text{Ca}}(t)$ is the calcium current at time t (ms), A is the current amplitude, and τ (ms) is the inactivation decay time constant.

The probability of a channel opening at the membrane potential V ($P_o(V)$) was obtained by multiplying $G/G_{\text{max}}(V)$ by $I/I_{\text{max}}(V)$. The window currents (I_w) were quantified by the equation.

$$I_w = G_{\text{max}} \times P_o(V) \times (V - V_{\text{rev}}) \quad (4)$$

To analyze the underlying mechanisms of the inactivation of Ca^{2+} currents, WT or R412M $\text{Ca}_v1.2$ currents were measured using extracellular (bath) CaCl_2 or BaCl_2 solutions in the same cells. Then, fractions of peak currents remaining after 200-ms depolarization were normalized to a peak current (r_{200}) at various test potentials. The fractions of CDI were calculated as^{7,8}:

$$f_{200} = (r_{200/\text{Ba}} - r_{200/\text{Ca}}) / r_{200/\text{Ba}}. \quad (5)$$

Statistical analysis. All analyses were performed using the SPSS 22.0 statistical package (IBM, Corp., Armonk, NY, USA). Differences between the two groups were evaluated using Mann–Whitney's U test. Differences were accepted as statistically significant for p values < 0.05. For comparisons among the three groups, one-way ANOVA or Kruskal–Wallis tests were performed. Bonferroni correction was used for post hoc pairwise comparison. Continuous patch-clamp data are expressed as a mean (\pm SEM or 95% CI).

Data availability

The datasets of the novel variant p.R412M in *CACNA1C* are registered in the dbSNP repository (ss2137544377, https://www.ncbi.nlm.nih.gov/SNP/snp_ss.cgi?ss=2137544377). Other datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

Received: 1 May 2022; Accepted: 1 November 2022

Published online: 08 November 2022

References

- Splawski, I. *et al.* $\text{Ca}_v1.2$ calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. *Cell* **119**, 19–31 (2004).
- Bauer, R., Timothy, K. W. & Golden, A. Update on the molecular genetics of Timothy syndrome. *Front. Pediatr.* **9**, 668546 (2021).
- Marcantoni, A., Calorio, C., Hidisoglu, E., Chiantia, G. & Carbone, E. $\text{Ca}_v1.2$ channelopathies causing autism: New hallmarks on Timothy syndrome. *Pflug. Arch.* **472**, 775–789 (2020).
- Splawski, I. *et al.* Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 8089–8096 (2005).

5. Richards, S. *et al.* Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet. Med.* **17**, 405–424 (2017).
6. Calorio, C. *et al.* Impaired chromaffin cell excitability and exocytosis in autistic Timothy syndrome TS2-neo mouse rescued by L-type calcium channel blockers. *J. Physiol.* **597**, 1705–1733 (2019).
7. Boczek, N. J. *et al.* Novel Timothy syndrome mutation leading to increase in *CACNA1C* window current. *Heart Rhythm* **12**, 211–219 (2015).
8. Dick, I. E., Joshi-Mukherjee, R., Yang, W. & Yue, D. T. Arrhythmogenesis in Timothy syndrome is associated with defects in Ca²⁺-dependent inactivation. *Nat. Commun.* **7**, 10370 (2016).
9. Yazawa, M. *et al.* Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. *Nature* **471**, 230–234 (2011).
10. Ferreira, G., Rios, E. & Reyes, N. Two components of voltage-dependent inactivation in Ca_v1.2 channels revealed by its gating currents. *Biophys. J.* **84**, 3662–3678 (2003).
11. Opatowsky, Y., Chen, C. C., Campbell, K. P. & Hirsch, J. A. Structural analysis of the voltage-dependent calcium channel β subunit functional core and its complex with the $\alpha 1$ interaction domain. *Neuron* **42**, 387–399 (2004).
12. Almagor, L. *et al.* The role of a voltage-dependent Ca²⁺ channel intracellular linker: A structure-function analysis. *J. Neurosci.* **32**, 7602–7613 (2012).
13. Liao, P., Yong, T. F., Liang, M. C., Yue, D. T. & Soong, T. W. Splicing for alternative structures of Ca_v1.2 Ca²⁺ channels in cardiac and smooth muscles. *Cardiovasc. Res.* **68**, 197–203 (2005).
14. Po, C. *et al.* Photosensitive epilepsy and long QT: Expanding Timothy syndrome phenotype. *Clin. Neurophysiol.* **130**, 2134–2136 (2019).
15. Bisabu, K. K. *et al.* Novel gain-of-function variant in *CACNA1C* associated with Timothy syndrome, multiple accessory pathways, and noncompacted cardiomyopathy. *Circ. Genom. Precis. Med.* **13**, e003123 (2020).
16. Dufendach, K. A. *et al.* Clinical outcomes and modes of death in Timothy syndrome a multicenter international study of a rare disorder. *JACC Clin. Electrophysiol.* **4**, 459–466 (2018).
17. Wemhoner, K. *et al.* Gain-of-function mutations in the calcium channel *CACNA1C* (Ca_v1.2) cause non-syndromic long-QT but not Timothy syndrome. *J. Mol. Cell Cardiol.* **80**, 186–195 (2015).
18. Gillis, J. *et al.* Long QT, syndactyly, joint contractures, stroke and novel *CACNA1C* mutation: Expanding the spectrum of Timothy syndrome. *Am. J. Med. Genet.* **158A**(1), 182–187 (2012).
19. Colson, C. *et al.* Unusual clinical description of adult with Timothy syndrome, carrier of a new heterozygote mutation of *CACNA1C*. *Eur. J. Med. Genet.* **62**, 103648 (2019).
20. Ozawa, J. *et al.* A novel *CACNA1C* mutation identified in a patient with Timothy syndrome without syndactyly exerts both marked loss- and gain-of-function effects. *HeartRhythm Case Rep.* **4**, 273–277 (2018).
21. Ye, D., Tester, D. J., Zhou, W., Papagiannis, J. & Ackerman, M. J. A pore-localizing *CACNA1C*-E1115K missense mutation, identified in a patient with idiopathic QT prolongation, bradycardia, and autism spectrum disorder, converts the L-type calcium channel into a hybrid nonselective monovalent cation channel. *Heart Rhythm* **16**, 270–278 (2019).
22. Hennessey, J. A. *et al.* A *CACNA1C* variant associated with reduced voltage-dependent inactivation, increased Ca_v1.2 channel window current, and arrhythmogenesis. *PLoS ONE* **9**, e106982 (2014).
23. Fukuyama, M. *et al.* Long QT syndrome type 8: Novel *CACNA1C* mutations causing QT prolongation and variant phenotypes. *Europace* **16**, 1828–1837 (2014).
24. Boczek, N. J. *et al.* Exome sequencing and systems biology converge to identify novel mutations in the L-type calcium channel, *CACNA1C*, linked to autosomal dominant long QT syndrome. *Circ. Cardiovasc. Genet.* **6**, 279–289 (2013).
25. Boczek, N. J. *et al.* Identification and functional characterization of a novel *CACNA1C*-mediated cardiac disorder characterized by prolonged QT intervals with hypertrophic cardiomyopathy, congenital heart defects, and sudden cardiac death. *Circ. Arrhythm. Electrophysiol.* **8**, 1122–1132 (2015).
26. Ozawa, J. *et al.* Differential diagnosis between catecholaminergic polymorphic ventricular tachycardia and long QT syndrome type 1-modified Schwartz score. *Circ. J.* **82**, 2269–2276 (2018).

Acknowledgements

This study was supported in part by MEXT KAKENHI Grant Number 15H04818 (to M.H.), 15K09689 (to S.O.), and 15K19375 (to M.F.) from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

Author contributions

O.J. carried out the preparation of mutant plasmid, most part of the electrophysiological studies, data analysis and drafted the manuscript. O.S. carried out the genetic studies and helped to draft the manuscript. D.M. carried out part of the electrophysiological studies and helped to draft the manuscript. Q.W. and F.M. participated in the preparation of mutant plasmid. T.F. provided advice for the electrophysiological studies. M.T. collected the clinical data of the patient and gave advice on the experiment. Y.M. and S.H. gave medical treatment to the patient and participated to the critical revision of the paper. S.A. and A.T. participated to the critical revision of the article. H.M. conceived the study, participated in its design and coordination and helped to draft the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-022-23512-2>.

Correspondence and requests for materials should be addressed to M.H.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022